Stockreport

Keros Therapeutics Announces Update on Enrollment in the Phase 2 TROPOS Trial

Keros Therapeutics, Inc. - common stock  (KROS) 
PDF LEXINGTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company foc [Read more]